Welcome!

News Feed Item

Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results

CALGARY, Aug. 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the second quarter ended June 30, 2014.

"Our randomized clinical program continued to advance during the quarter as we recently reported the completion of enrollment in a Phase II study using REOLYSIN® in combination with carboplatin and paclitaxel in pancreatic cancer patients," said Dr. Brad Thompson, President and CEO of Oncolytics. "We also strengthened our board, adding two directors with significant financial and public company experience."

Selected Highlights

Since April 1, 2014, selected highlights announced by the Company include:

Clinical and Preclinical Data

  • Completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045);
  • Early results from a translational study looking at intravenous administration of REOLYSIN® to patients with primary or metastatic brain tumors was presented at the ASCO Annual Meeting in Chicago, IL;
  • Final data from the Company's randomized, double-blinded clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers;
  • A series of presentations by research collaborators at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK covering:
    • early clinical research showing that intravenously delivered REOLYSIN® can cross the blood brain barrier to access tumours in the brains of humans;
    • preclinical research examining the synergies associated with treatment in animal models with GM-CSF prior to administering REOLYSIN®;
    • preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines; and
    • preclinical research into the treatment of hepatocellular carcinoma associated with infection by Hepatitis B and Hepatitis C.

Governance

  • The nomination and election of Ms. Linda Hohol and Ms. Angela Holtham to the Company's board of directors; and

Financial

  • At June 30, 2014 the Company reported $18.9 million in cash, cash equivalents and short-term investments.

 



ONCOLYTICS BIOTECH INC.
INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)






June 30,

2014

$


December 31,

2013

$

Assets




Current assets




Cash and cash equivalents

16,880,730


25,220,328

Short-term investments

2,031,685


2,001,644

Accounts receivable

54,391


105,853

Prepaid expenses

609,538


361,743

Total current assets

19,576,344


27,689,568





Non-current assets




Property and equipment

470,217


532,459

Total non-current assets

470,217


532,459





Total assets

20,046,561


28,222,027





Liabilities And Shareholders' Equity




Current Liabilities




Accounts payable and accrued liabilities

3,667,076


6,008,661

Total current liabilities

3,667,076


6,008,661





Shareholders' equity








Share capital
  Authorized: unlimited   Issued:




   June 30, 2014 – 87,537,397




   December 31, 2013 – 84,803,818

232,303,714


228,612,564

Warrants


376,892

Contributed surplus

25,538,706


24,491,212

Accumulated other comprehensive loss

87,679


79,698

Accumulated deficit

(241,550,614)


(231,347,000)

Total shareholders' equity

16,379,485


22,213,366

Total liabilities and equity

20,046,561


28,222,027

 

 


ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)










Three Month
Period
Ending June
30, 2014
$


Three Month
Period
Ending June
30, 2013
$


Six Month
Period
Ending June
30, 2014
$


Six Month
Period
Ending June
30, 2013
$









Expenses








  Research and development

3,555,055


3,804,307


7,733,389


8,921,351

  Operating

1,209,815


1,320,742


2,601,069


2,885,493

Operating loss

(4,764,870)


(5,125,049)


(10,334,458)


(11,806,844)

  Interest

50,253


105,368


138,240


180,327

Loss before income taxes

(4,714,617)


(5,019,681)


(10,196,218)


(11,626,517)

 Income tax expense

(3,546)



(7,396)


Net loss

(4,718,163)


(5,019,681)


(10,203,614)


(11,626,517)

Other comprehensive income items that may be

  reclassified to net loss
















Translation adjustment

26,675


73,451


7,981


107,639









Net comprehensive loss

(4,691,488)


(4,946,230)


(10,195,633)


(11,518,878)

Basic and diluted loss per common share

(0.05)


(0.06)


(0.12)


(0.14)

Weighted average number of shares
(basic and diluted)

86,581,854


84,758,818


85,869,008


82,276,330









  

 


ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)














Share Capital

$


Contributed
Surplus

$


Warrants

$


Accumulated
Other
Comprehensive
Loss

$


Accumulated
Deficit

$


Total

$

As at December 31, 2012

198,155,091


24,126,265


376,892


(57,115)


(207,814,353)


14,786,780













Net loss and
comprehensive loss




107,639


(11,626,517)


(11,518,878)

Issued, pursuant to a
bought deal financing

30,218,797






30,218,797

Exercise of stock options

139,676


(34,687)





104,989













Share based compensation


250,853





250,853

As at June 30, 2013

228,513,564


24,342,431


376,892


50,524


(219,440,870)


33,842,541














Share Capital

$


Contributed
Surplus

$


Warrants

$


Accumulated
Other
Comprehensive
Loss

$


Accumulated
Deficit

$


Total

$













As at December 31, 2013

228,612,564


24,491,212


376,892


79,698


(231,347,000)


22,213,366













Net loss and
comprehensive loss




7,981


(10,203,614)


(10,195,633)

Issued, pursuant to Share
Purchase Agreement

3,691,150






3,691,150

Expired warrants


376,892


(376,892)
















Share based compensation


670,602





670,602

As at June 30, 2014

232,303,714


25,538,706



87,679


(241,550,614)


16,379,485

 

 

 


ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)










Three Month
Period
Ending June
30, 2014

$


Three Month
Period
Ending June
30, 2013

$


Six Month
Period
Ending June
30, 2014

$


Six Month
Period
Ending June
30, 2013

$









Operating Activities








Net loss for the period

(4,718,163)


(5,019,681)


(10,203,614)


(11,626,517)

  Amortization - property and equipment

38,512


25,565


78,169


50,146

  Share based compensation

366,005


129,997


670,602


250,853

  Unrealized foreign exchange loss

(74,059)


209,804


(49,989)


(97,849)

Net change in non-cash working capital

(1,392,530)


(455,283)


(2,439,481)


(2,096,453)

Cash used in operating activities

(5,780,235)


(5,109,598)


(11,944,313)


(13,519,820)

Investing Activities








Acquisition of property and equipment

(1,239)


(132,164)


(17,219)


(147,302)

Purchase of short-term investments



(30,041)


(32,416)

Cash used in investing activities

(1,239)


(132,164)


(47,260)


(179,718)

Financing Activities








Proceeds from exercise of stock options and

  warrants




104,989

Proceeds from Share Purchase Agreement

2,502,708



3,691,150


Proceeds from public offering


11,735



30,218,797

Cash provided by financing activities

2,502,708


11,735


3,691,150


30,323,786

Increase in cash

(3,278,766)


(5,230,027)


(8,300,423)


16,624,248

Cash and cash equivalents, beginning of period

20,155,907


41,519,657


25,220,328


19,323,541

Impact of foreign exchange on cash and cash

  equivalents

3,589


(136,353)


(39,175)


205,488

Cash and cash equivalents, end of period

16,880,730


36,153,277


16,880,730


36,153,277

 

To view the Company's Second Quarter 2014 Consolidated Financial Statements, related Notes to Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's quarterly filings which will be available on www.sedar.com and on www.oncolyticsbiotech.com/for-investors/financials.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2014 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
"We are a leader in the market space called network visibility solutions - it enables monitoring tools and Big Data analysis to access the data and be able to see the performance," explained Shay Morag, VP of Sales and Marketing at Niagara Networks, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
"This is specifically designed to accommodate some of the needs for high availability and failover in a network managed system for the major Korean corporations," stated Thomas Masters, Managing Director at InfranicsUSA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Unsecured IoT devices were used to launch crippling DDOS attacks in October 2016, targeting services such as Twitter, Spotify, and GitHub. Subsequent testimony to Congress about potential attacks on office buildings, schools, and hospitals raised the possibility for the IoT to harm and even kill people. What should be done? Does the government need to intervene? This panel at @ThingExpo New York brings together leading IoT and security experts to discuss this very serious topic.
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
CloudJumper, a Workspace as a Service (WaaS) platform innovator for agile business IT, has been recognized with the Customer Value Leadership Award for its nWorkSpace platform by Frost & Sullivan. The company was also featured in a new report(1) by the industry research firm titled, “Desktop-as-a-Service Buyer’s Guide, 2016,” which provides a comprehensive comparison of DaaS providers, including CloudJumper, Amazon, VMware, and Microsoft.